IMREVITE Trademark

Trademark Overview


On Tuesday, September 15, 2020, a trademark application was filed for IMREVITE with the United States Patent and Trademark Office. The USPTO has given the IMREVITE trademark a serial number of 90182567. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 23, 2024. This trademark is owned by Bristol-Myers Squibb Company. The IMREVITE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
imrevite

General Information


Serial Number90182567
Word MarkIMREVITE
Filing DateTuesday, September 15, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 23, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 22, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 22, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Friday, September 18, 2020NEW APPLICATION ENTERED
Thursday, October 22, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, November 18, 2020ASSIGNED TO EXAMINER
Thursday, November 19, 2020NON-FINAL ACTION WRITTEN
Thursday, November 19, 2020NON-FINAL ACTION E-MAILED
Thursday, November 19, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, May 17, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, May 17, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, May 17, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 18, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 2, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 22, 2021PUBLISHED FOR OPPOSITION
Tuesday, June 22, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 17, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 8, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, February 8, 2022SOU EXTENSION 1 FILED
Tuesday, February 8, 2022SOU EXTENSION 1 GRANTED
Thursday, February 10, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 27, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, July 27, 2022SOU EXTENSION 2 FILED
Wednesday, July 27, 2022SOU EXTENSION 2 GRANTED
Friday, July 29, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 13, 2023SOU TEAS EXTENSION RECEIVED
Monday, February 13, 2023SOU EXTENSION 3 FILED
Monday, February 13, 2023SOU EXTENSION 3 GRANTED
Wednesday, February 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, August 2, 2023SOU EXTENSION 4 FILED
Wednesday, August 2, 2023SOU EXTENSION 4 GRANTED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, August 4, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 12, 2024SOU TEAS EXTENSION RECEIVED
Friday, January 12, 2024SOU EXTENSION 5 FILED
Tuesday, January 30, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, January 31, 2024SOU EXTENSION 5 GRANTED
Thursday, February 1, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 23, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, September 23, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED